A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
Status:
Completed
Trial end date:
2000-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to find out whether HIV-positive patients whose immune systems have
improved after receiving anti-HIV treatment should take azithromycin to prevent Mycobacterium
avium complex (MAC) disease. This study also examines the possibility of putting off MAC
prevention treatment in patients who respond well to anti-HIV drug therapy.
Azithromycin is approved for the prevention of MAC disease in people with HIV and low CD4
cell counts. However, some people who have taken azithromycin have been found to carry
antibiotic-resistant bacteria (germs that can grow despite the presence of drugs used to kill
them). It is not known whether the risks associated with taking azithromycin outweigh the
risk of getting MAC disease.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)